<tmx version="1.4">
 <header adminlang="LC" srclang="en" o-tmf="PlainText" creationtool="bitextor" creationtoolversion="8.2" datatype="PlainText" segtype="sentence" creationdate="20221218T071823" o-encoding="utf-8">
 </header>
 <body>
   <tu tuid="1" datatype="Text">
    <prop type="score-hunalign">2.01875</prop>
    <prop type="score-bicleaner">0.638</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>Delivery to a Wholesaler shall be carried out in accordance with agreement between the Supplier and the Wholesaler, and as a minimum in accordance with the terms of this Framework Agreement, see Appendix 5.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Levering til grossister skal for &#248;vrig skje i henhold til de avtalene Leverand&#248;ren har med grossistene, og minimum i henhold til betingelsene i denne avtalen, se bilag 5.</seg>
    </tuv>
   </tu>
   <tu tuid="2" datatype="Text">
    <prop type="score-hunalign">1.70323</prop>
    <prop type="score-bicleaner">0.616</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>Requirements for membership in a return scheme</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Krav til medlemskap i returordning</seg>
    </tuv>
   </tu>
   <tu tuid="3" datatype="Text">
    <prop type="score-hunalign">6.888</prop>
    <prop type="score-bicleaner">0.678</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>6 Ordering and Distribution</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>6 Bestilling og distribusjon</seg>
    </tuv>
   </tu>
   <tu tuid="4" datatype="Text">
    <prop type="score-hunalign">1.03816</prop>
    <prop type="score-bicleaner">0.530</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Innspillsskjema/Innspill%20fra%20firma%20ID2021_130_Entyvio%20Pouchitis_081121.pdf.converted</prop>
     <seg>therapies are sometimes used (off-label) following failure of conventional treatment.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Innspillsskjema/Innspill%20fra%20nevrologisk%20avdeling%20a-hus%20ID2021_075.pdf.converted</prop>
     <seg>Et ikke-medikamentelt alternativ (SPG-stimulator) er ikke lenger tilgjengelig.</seg>
    </tuv>
   </tu>
   <tu tuid="5" datatype="Text">
    <prop type="score-hunalign">2.79353</prop>
    <prop type="score-bicleaner">0.582</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>The Framework Agreement applies to all use of the pharmaceutical drug cf. Appendix 1 and Appendix 3.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Rammeavtalen gjelder for all bruk av legemiddelet i henhold til bilag 1 og bilag 3 Kriterier for medisinsk behandling.</seg>
    </tuv>
   </tu>
   <tu tuid="6" datatype="Text">
    <prop type="score-hunalign">4.79333</prop>
    <prop type="score-bicleaner">0.660</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002_Forslag.pdf.converted</prop>
     <seg>response rates over time measured as ACR 20 response</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002B.pdf.converted</prop>
     <seg>&#248;kende responsrate over tid, m&#229;lt som ACR 20 respons.</seg>
    </tuv>
   </tu>
   <tu tuid="7" datatype="Text">
    <prop type="score-hunalign">2.1125</prop>
    <prop type="score-bicleaner">0.640</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002_Forslag.pdf.converted</prop>
     <seg>o Patient responding to treatment have continued effect over time (current data cut 52 weeks)</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002B.pdf.converted</prop>
     <seg>o Pasienter som respondere til behandling har kontinuerlig effekt over tid (52 uker)</seg>
    </tuv>
   </tu>
   <tu tuid="8" datatype="Text">
    <prop type="score-hunalign">2.25252</prop>
    <prop type="score-bicleaner">0.578</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>Return to the Wholesaler and destruction will be carried out in accordance with the Wholesaler&#180;s internal procedures and terms, unless otherwise is agreep upon and specified in Appendix 5.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Retur til avtalegrossist og destruksjon vil bli utf&#248;rt i henhold til avtalegrossistens interne prosedyrer og betingelser, dersom intet annet er avtalt i bilag 5.</seg>
    </tuv>
   </tu>
   <tu tuid="9" datatype="Text">
    <prop type="score-hunalign">8.442</prop>
    <prop type="score-bicleaner">0.504</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>3 Documents in the Framework Agreement</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>3 Rammeavtalens dokumenter</seg>
    </tuv>
   </tu>
   <tu tuid="10" datatype="Text">
    <prop type="score-hunalign">4.4325</prop>
    <prop type="score-bicleaner">0.678</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002_Forslag.pdf.converted</prop>
     <seg>response rates over time measured as PASI-75 response</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002B.pdf.converted</prop>
     <seg>responsrate over tid m&#229;lt ved PASI 75 respons.</seg>
    </tuv>
   </tu>
   <tu tuid="11" datatype="Text">
    <prop type="score-hunalign">1.01018</prop>
    <prop type="score-bicleaner">0.526</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>The Responsible Clinician and the Health Trust have the sole responisiblity for the medical treatmets of Patients and for all use of the pharmaceutical drug.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Kliniker og helseforetak er eneansvarlig for medisinsk behandling av pasienter, og for bruk av legemiddelet.</seg>
    </tuv>
   </tu>
   <tu tuid="12" datatype="Text">
    <prop type="score-hunalign">2.19952</prop>
    <prop type="score-bicleaner">0.556</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>Return to the Hospital Pharmacy Enterprise and destruction will be carried out in accordance with the Hospital Pharmacy Enterprise&#180;s internal procedures, unless otherwise is agreep upon and specified in Appendix 4.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Retur til sykehusapoteket og destruksjon vil bli utf&#248;rt i henhold til sykehusapotekets interne prosedyrer, dersom intet annet er avtalt i bilag 4.</seg>
    </tuv>
   </tu>
   <tu tuid="13" datatype="Text">
    <prop type="score-hunalign">4.98616</prop>
    <prop type="score-bicleaner">0.670</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>5 Costs of using the pharmaceutical drug</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>5 Kostnader ved bruk av legemiddelet</seg>
    </tuv>
   </tu>
   <tu tuid="14" datatype="Text">
    <prop type="score-hunalign">2.02042</prop>
    <prop type="score-bicleaner">0.602</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>The pharmaceutical drug shall be delivered not later than 14 days after the Customer has made an Order, unless otherwise is agreed upon and specified in the Treatment Agreement and Appendix 4.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Legemiddelet skal leveres senest innen 14 dager fra Kunden har foretatt bestilling, med mindre annet er avtalt og spesifisert i behandlingsavtalen og bilag 4.</seg>
    </tuv>
   </tu>
   <tu tuid="15" datatype="Text">
    <prop type="score-hunalign">3.27857</prop>
    <prop type="score-bicleaner">0.646</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002_Forslag.pdf.converted</prop>
     <seg>o About 40% of patients respond to treatment at week 16 with increasing</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002B.pdf.converted</prop>
     <seg>o Rundt 40% av pasienter responderer p&#229; behandling ved uke 16, med</seg>
    </tuv>
   </tu>
   <tu tuid="16" datatype="Text">
    <prop type="score-hunalign">1.82929</prop>
    <prop type="score-bicleaner">0.608</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/National%20Standard%20Agreement%20as%20of%20201316.pdf.converted</prop>
     <seg>It is required that products covered by this Framework Agreement are produced in a lawful and ethical sound manner, see Appendix 6 &#8211; &#171;Ethical requirements for the Supplier&#187;.</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Administrativt%20%28brukes%20kun%20av%20sekretariatet%21%29/Nasjonal%20standardavtale%20lm%20uten%20MT%20pr.%20200316.pdf.converted</prop>
     <seg>Det er et krav at de produkter som avtalen omfatter er produsert p&#229; en lovlig og etisk forsvarlig m&#229;te, se bilag 6 &#8211; &#171;Etiske krav til leverand&#248;r&#187;.</seg>
    </tuv>
   </tu>
   <tu tuid="17" datatype="Text">
    <prop type="score-hunalign">3.3</prop>
    <prop type="score-bicleaner">0.646</prop>
    <prop type="type">1:1</prop>
    <tuv xml:lang="en">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002_Forslag.pdf.converted</prop>
     <seg>o About 30% of patients respond to treatment at week 16 with increasing</seg>
    </tuv>
    <tuv xml:lang="nb">
     <prop type="source-document">https://nyemetoder.no/Documents/Forslag/ID2015_002B.pdf.converted</prop>
     <seg>o Ca 30% av pasientene responderer p&#229; behandling ved uke 16, med &#248;kende</seg>
    </tuv>
   </tu>
   </body>
</tmx>